KATIE CAIN: Open Payments
NPI 1407697063 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$490 in 19 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $455 · 2025 $490
Food & beverage: $490
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $154 |
| Novartis Pharmaceuticals Corporation | 1 | $104 |
| OPKO Pharmaceuticals, LLC | 3 | $50 |
| Ardelyx, Inc. | 2 | $49 |
| Vifor Pharma, Inc. | 2 | $38 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $32 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
Products named: JYNARQUE, Vanrafia, RAYALDEE, IBSRELA, Veltassa, TARPEYO, VOYXACT, Yorvipath.
Industry payments across FL — which companies pay providers there.
